168 related articles for article (PubMed ID: 34181339)
21. The Cytotoxic and Antimigratory Activity of Brazilin-Doxorubicin on MCF-7/HER2 Cells.
Jenie RI; Handayani S; Susidarti RA; Udin LZ; Meiyanto E
Adv Pharm Bull; 2018 Aug; 8(3):507-516. PubMed ID: 30276148
[No Abstract] [Full Text] [Related]
22. Curcumin improves the therapeutic efficacy of Listeria(at)-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1.
Singh M; Ramos I; Asafu-Adjei D; Quispe-Tintaya W; Chandra D; Jahangir A; Zang X; Aggarwal BB; Gravekamp C
Cancer Med; 2013 Aug; 2(4):571-82. PubMed ID: 24156030
[TBL] [Abstract][Full Text] [Related]
23. Diterpenoid natural compound C4 (Crassin) exerts cytostatic effects on triple-negative breast cancer cells via a pathway involving reactive oxygen species.
Richards CE; Vellanki SH; Smith YE; Hopkins AM
Cell Oncol (Dordr); 2018 Feb; 41(1):35-46. PubMed ID: 29134467
[TBL] [Abstract][Full Text] [Related]
24. Cycle arrest and apoptosis in MDA-MB-231/Her2 cells induced by curcumin.
Sun SH; Huang HC; Huang C; Lin JK
Eur J Pharmacol; 2012 Sep; 690(1-3):22-30. PubMed ID: 22705896
[TBL] [Abstract][Full Text] [Related]
25. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
[TBL] [Abstract][Full Text] [Related]
26. Synergistic cytotoxic effect of genistein and doxorubicin on drug-resistant human breast cancer MCF-7/Adr cells.
Xue JP; Wang G; Zhao ZB; Wang Q; Shi Y
Oncol Rep; 2014 Oct; 32(4):1647-53. PubMed ID: 25109508
[TBL] [Abstract][Full Text] [Related]
27. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
[TBL] [Abstract][Full Text] [Related]
28. Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51.
Lee JO; Kang MJ; Byun WS; Kim SA; Seo IH; Han JA; Moon JW; Kim JH; Kim SJ; Lee EJ; In Park S; Park SH; Kim HS
Breast Cancer Res; 2019 Oct; 21(1):115. PubMed ID: 31640742
[TBL] [Abstract][Full Text] [Related]
29. The integrative bioinformatic analysis deciphers the predicted molecular target gene and pathway from curcumin derivative CCA-1.1 against triple-negative breast cancer (TNBC).
Novitasari D; Jenie RI; Kato JY; Meiyanto E
J Egypt Natl Canc Inst; 2021 Aug; 33(1):19. PubMed ID: 34337682
[TBL] [Abstract][Full Text] [Related]
30. Intracellular trafficking and cytotoxicity of a gelatine-doxorubicin conjugate in two breast cancer cell lines.
Alvi MM; Nicoletto RE; Eshmawi BA; Kim HK; Cammarata CR; Ofner CM
J Drug Target; 2020 Jun; 28(5):487-499. PubMed ID: 31601131
[TBL] [Abstract][Full Text] [Related]
31. Triple Negative Breast Cancer Depends on Sphingosine Kinase 1 (SphK1)/Sphingosine-1-Phosphate (S1P)/Sphingosine 1-Phosphate Receptor 3 (S1PR3)/Notch Signaling for Metastasis.
Wang S; Liang Y; Chang W; Hu B; Zhang Y
Med Sci Monit; 2018 Apr; 24():1912-1923. PubMed ID: 29605826
[TBL] [Abstract][Full Text] [Related]
32. New bis(hydroxymethyl) alkanoate curcuminoid derivatives exhibit activity against triple-negative breast cancer in vitro and in vivo.
Hsieh MT; Chang LC; Hung HY; Lin HY; Shih MH; Tsai CH; Kuo SC; Lee KH
Eur J Med Chem; 2017 May; 131():141-151. PubMed ID: 28319780
[TBL] [Abstract][Full Text] [Related]
33. CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers.
Cheriyan VT; Muthu M; Patel K; Sekhar S; Rajeswaran W; Larsen SD; Polin L; Levi E; Singh M; Rishi AK
Oncotarget; 2016 Nov; 7(45):73370-73388. PubMed ID: 27687593
[TBL] [Abstract][Full Text] [Related]
34. PAC down-regulates estrogen receptor alpha and suppresses epithelial-to-mesenchymal transition in breast cancer cells.
Al-Howail HA; Hakami HA; Al-Otaibi B; Al-Mazrou A; Daghestani MH; Al-Jammaz I; Al-Khalaf HH; Aboussekhra A
BMC Cancer; 2016 Jul; 16():540. PubMed ID: 27465411
[TBL] [Abstract][Full Text] [Related]
35. Demethoxycurcumin inhibits energy metabolic and oncogenic signaling pathways through AMPK activation in triple-negative breast cancer cells.
Shieh JM; Chen YC; Lin YC; Lin JN; Chen WC; Chen YY; Ho CT; Way TD
J Agric Food Chem; 2013 Jul; 61(26):6366-75. PubMed ID: 23777448
[TBL] [Abstract][Full Text] [Related]
36. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
[TBL] [Abstract][Full Text] [Related]
37. Rubioncolin C, a natural naphthohydroquinone dimer isolated from Rubia yunnanensis, inhibits the proliferation and metastasis by inducing ROS-mediated apoptotic and autophagic cell death in triple-negative breast cancer cells.
Li L; Wang J; Feng L; Fan J; Wang J; Tan N; Wang Z
J Ethnopharmacol; 2021 Sep; 277():114184. PubMed ID: 33961996
[TBL] [Abstract][Full Text] [Related]
38. Curcumin Rescues Doxorubicin Responsiveness via Regulating Aurora a Signaling Network in Breast Cancer Cells.
Biswas S; Mahapatra E; Ghosh A; Das S; Roy M; Mukherjee S
Asian Pac J Cancer Prev; 2021 Mar; 22(3):957-970. PubMed ID: 33773562
[TBL] [Abstract][Full Text] [Related]
39. Synergistic Effect of SH003 and Doxorubicin in Triple-negative Breast Cancer.
Woo SM; Kim AJ; Choi YK; Shin YC; Cho SG; Ko SG
Phytother Res; 2016 Nov; 30(11):1817-1823. PubMed ID: 27476488
[TBL] [Abstract][Full Text] [Related]
40. 1-Chromonyl-5-Imidazolylpentadienone Demonstrates Anti-Cancer Action against TNBC and Exhibits Synergism with Paclitaxel.
Modi K; Lawson S; Chen G; Tumuluri D; Rekhtman I; Kurtz M; Brailoiu GC; Chen QH; Lakshmikuttyamma A
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32806551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
